# A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

> **NCT00263276** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 389 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** dapagliflozin
- **DRUG:** dapagliflozin
- **DRUG:** dapagliflozin
- **DRUG:** dapagliflozin
- **DRUG:** dapagliflozin
- **DRUG:** placebo
- **DRUG:** metformin

## Key facts

- **NCT ID:** NCT00263276
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 389 (ACTUAL)
- **Last updated:** 2016-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263276, "A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00263276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*